ATCC

Did you miss our posters or presentation at the recent SLAS conference? No problem! Download your PDF copy to see our research on the development and validation of our new ThawReady™ products! Accelerate Cell-Based Assays with the ThawReady™ THP-1 NF-κB-Luc2 Reporter Line - https://ow.ly/BFCj50V78cR Development of the ThawReady™ THP-1 Product for Cell-Based Assays - https://ow.ly/F7nR50V78cQ From Curiosity to Breakthroughs: Accelerate Your Drug Development with Assay Ready Cells - https://ow.ly/PkzP50V78cT

Ensure reliable and reproducible results in your avian influenza research with ATCC's Quantitative Synthetic Avian Influenza Virus (H5N1) RNA. Designed for assay development, verification, and validation, this high-quality synthetic molecular standard helps researchers accurately determine viral load using qPCR. At ATCC, we are committed to supporting the scientific community with high-quality synthetic molecular standards. Explore Standards: https://ow.ly/9GGt50V6fxw #AvianInfluenza #SyntheticStandards #Research #ATCC #qPCR

For Sir Alexander Fleming, described by his fellow researchers as “untidy,” finding unusual growth in his bacterial cultures was a regular occurrence. While working with Staphylococcus aureus in the fall of 1928, he noticed that one particular fungal contaminant appeared to have a lytic effect on the surrounding bacteria. Through controlled experiments with this mold, identified by his colleague Charles J. La Touche as Penicillium rubens, he proved the inhibitory effect against medically relevant infectious bacteria. While initially referring to the substance as “mould juice,” he later named the compound penicillin. Sir Flemming published his results to little fanfare and less acceptance among the medical community. It was only after the widespread use of sulfonamides to treat infection and the introduction of concentrated penicillin by Sir Ernst Chain and Howard Florey in 1940 that the medical community finally took notice. In May 1944, ATCC acquired the so called “Fleming strain” of Penicillium from the Northern Regional Research Laboratory (NRRL) of the USDA. Over the last 80 years, the use of antimicrobial compounds has become the primary treatment for bacterial infections worldwide. Against the backdrop of growing antibacterial resistance, this strain continues to serve an important role in the development of new treatments for bacterial infections. See the fungi: https://ow.ly/B02150V5vsP Written by: Kendra Grosso

The mouse cell line NIH/3T3 (ATCC® CRL-1658™) is a spontaneously immortalized fibroblast cell line. NIH/3T3 cells were developed by George Todaro and Howard Green in 1962 and is one of the most widely utilized cell lines in general cell biology, cancer research, and transfection studies. These cells were originally known for their strong contact inhibition and are widely used in assays to determine a gene of interest’s potential to become oncogenic. Introduction of an overexpressed gene in NIH/3T3 cells may promote morphological changes that allows the cells to create dense foci areas. Over time, the NIH/3T3 cells have emerged as a multi-clonal cell population resulting in cell transformation and the loss of contact inhibition. ATCC® recently restored this property through single cell cloning, generating a clonal derivative NIH/3T3.2 (ATCC® CRL-1658.2™), that maintains the original contact inhibition property associated with these cells. ATCC® is currently the only biorepository that has NIH/3T3 cells with the restored contact inhibition property within their collection. See the cell lines: NIH/3T3 👉 https://ow.ly/Vec350V5tfa NIH/3T3.2 👉 https://ow.ly/rzLj50V5tf9 Written by: Paul Lovell, PhD

Dive into our latest #blog post to learn about the use of ThawReady™ THP-1 NF-κB-LUC2 cells in EV-mediated repair assays. Read now: https://ow.ly/8JC850V4xUG #CredibleConversations

Gain valuable insights into the impacts of influenza outbreaks and the latest diagnostic resources. Join our webinar on Thursday, March 13 at 12 PM ET to stay updated. Register now: https://ow.ly/oEL050V3QCC #Influenza #AvianFlu #Webinar #Diagnostics #ATCC

In 2005, a study by Mojica et al. showed that short-repeated DNA sequences in ATCC® 700294™ were derived from mobile genetic elements. These repetitive genomic loci, also known as clustered regularly interspaced short palindromic repeats (CRISPR), were shown to confer immunity to foreign extrachromosomal elements. Later in 2012, the CRISPR-Cas9 endonuclease gene, cloned from ATCC® 700294™, was used in groundbreaking research by Jennifer Doudna and Emmanuelle Charpentier for programmable gene editing. The use of CRISPR-Cas9 for genome editing has revolutionized the biotechnology field and ultimately led to the Nobel Prize in Chemistry for Drs. Jennifer Doudna and Emmanuel Charpentier. See the bacteria: https://ow.ly/hMvO50V3HFj Written by: Scott Nguyen, PhD

Join us for Episode 26 of our podcast: "ThawReady™ - Transforming Cryopreservation for Instant Cell Functionality". 🎙️ In this episode, Dr. Chakraborty delves into the groundbreaking ThawReady™ Assay Ready Cells developed by his team. Discover how these innovative cells minimize injuries caused by traditional cryopreservation methods, allowing for immediate use after thawing and reducing the time and effort required for cell culture. Dr. Chakraborty also shares the strategic approach ATCC took, leveraging advanced omics technologies to understand and mitigate cellular injuries. Learn about the broader implications of this technology, including cost savings and enhanced efficiency, and the importance of compatibility with new characterization technologies and standardization. Don't miss this insightful discussion on the future of cryobiology! 🎧 Listen now: https://ow.ly/m9W050V36xg #Cryobiology #ThawReady #CellCulture #Biotechnology #Podcast

Unbeknownst to most, today’s world of modern medicine relies heavily on Chinese hamster ovarian (CHO) cells. These workhorse cells readily survive in bioprocessing environments because they are extremely tolerant of variations in pH, oxygen levels, temperature, and pressure, among other variables. When researchers discovered in the 1950s that CHO cells could multiply rapidly and produce large amounts of protein, they quickly became critical in the development of protein-based therapeutics. These therapeutics have been instrumental in treating a wide array of medical conditions, including cancer, hemophilia, psoriasis, hormone imbalances, and more. Today, scientists use gene-editing tools to engineer CHO cells to produce specific therapeutic antibodies or proteins—this has contributed to the production of most of the biologic drugs in the US and over half of the therapeutic antibodies used in cancer treatments. See the cells: https://ow.ly/H9pN50V2bUr Written by: Ana Melentijevic Eckert

We provide a portfolio of secure biomaterial deposit options to serve every need of the scientific research community. Learn more about our deposit services: https://ow.ly/sATN50V0eBm